Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sochett

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
American Journal of Physiology. Renal Physiology|October 14, 2016
The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetesKevin D Burns, Yuliya Lytvyn, Farid H Mahmud, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Canadian Journal of Kidney Health and Disease|January 27, 2018
Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and FunctionAdeera Levin, Evan Adams, Brendan J Barrett, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
American Journal of Physiology. Renal Physiology|October 14, 2016
The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetesKevin D Burns, Yuliya Lytvyn, Farid H Mahmud, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Canadian Journal of Kidney Health and Disease|January 27, 2018
Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and FunctionAdeera Levin, Evan Adams, Brendan J Barrett, et al.
Pageof 13